Therefore, ongoing prospective trials examining the effects of SGLT2 inhibitors on CV biomarkers in T2D patients with documented HF may further elucidate the underlying mechanisms and clinical application of SGLT2 inhibitors in CV disease and HF care [9]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.